1.Clinical Efficacy Evaluation of Leukotriene Receptor Antagonists for Treatment of Coexisting Asthma and Allergic Rhinitis in Children
Dehui CHEN ; Yuneng LIN ; Xiaoan PAN
International Journal of Pediatrics 2007;0(04):-
Objective To evaluate the efficacy of Leukotriene receptor antagonists in treatment of patients with asthma and allergic rhinitis(AR).Methods This study was a 24-week,randomized,control open trial in which 100 children,who were diagnosed as mild to severe persistent coexisting asthma and AR,were enrolled.All cases were collected from pediatric out-patient department of the First Affiliated Hospital of Guangzhou Medical College from October 1st,2005 to April 30th,2006 and were divided into three groups.Montelukast group(1 group):inhated budesonide turbuhaler and oral singulair(5mg/Qn);Intranasal corticosteroids group(2 group):inhaled budesonide turbuhaler and intranasal budesonide nasal spray(64?g/Qd);Control group(Control group):only inhaled budesonide turbuhaler.Efficacy was assessed by recording daytime and nighttime symptom scores,nasal symptom scores,the times of acute episode,the symptomfree days,the requirement for the weekly beta 2-receptor agonist and the medication scores,using a daily diary card and the recording work were repeated per fo ur weeks in totally six months.Lung function(forced expiratory volume at 1 s inpredicted normal,FEV1%) and nasal eosinophil count had been tested three times:before treatment,after treatment of 8th and 24th week.Results 1 group and 2 group,compared with the prior treatment(P0.05);1 group was more statistically significant than 2 group in improving FEV1(P
2.Value of octreotide suppression test in predicting the efficacy of long-acting somatostatin receptor ligands in pituitary GH adenomas
Ran LI ; Lian DUAN ; Hui PAN ; Shengmin YANG ; Linjie WANG ; Hongbo YANG ; Fengying GONG ; Xiaoan KE ; Meiping CHEN ; Huijuan ZHU
Chinese Journal of Endocrinology and Metabolism 2022;38(4):288-293
Objective:To explore the value of octreotide suppression test(OST) in predicting the efficacy of somatostatin receptor ligands(SRLs) in the treatment of active acromegaly.Methods:The clinical data of 76 patients with active acromegaly from 2011 to 2020 was retrospectively analyzed. OST was carried out as follows: After an overnight fasting and baseline sampling of growth hormone(GH), 100 μg octreotide was subcutaneously injected, and sampling for GH was obtained every 2 hours for 8 hours. All patients were treated with SRLs for at least 3 months. A good GH response is defined as a post-treatment random GH<1 μg/L or >80% fall compared with the baseline GH. A good insulin-like growth factor Ⅰ(IGF-Ⅰ) response is defined as IGF-Ⅰ<1.3 upper limit of normal(ULN) or >50% reduction compared with the baseline. If both GH and IGF-Ⅰ fulfill the criteria of a good response, it is defined as a good GH and IGF-Ⅰ response.Results:The baseline level of GH during OST was 15.00(6.38, 34.20) μg/L, the median time to reach the nadir GH was(3.65±1.65) hours, and the nadir GH level was 1.47(0.50, 4.19) μg/L. The median GH suppression rate was 89.12%(72.71%, 95.09%). When the cutoff value of GH suppression rate in predicting a good GH response was 89.32%, the area under the curve(AUC) was 0.74, with a sensitivity of 81.80% and specificity of 66.00%. When the cutoff value of GH suppression rate in predicting a good IGF-Ⅰ response was 93.14%, the AUC was 0.64, with a sensitivity of 50.00% and specificity of 75.60%. When the GH suppression rate was 90.71%, the AUC was 0.78, with the sensitivity of 83.30% and specificity of 70.00% in predicting a good GH and IGF-Ⅰ response. Compared with GH/IGF-Ⅰ non-responders, GH/IGF-Ⅰ responders displayed lower nadir GH during OST, higher GH suppression rate and IGF-Ⅰ reduction rate, and lower ratio of IGF-1 to ULN( P<0.05). Conclusion:GH suppression rate during the OST is a valuable predictor to evaluate the efficacy of SRLs in patients with acromegaly, with the highest sensitivity and specificity when the cutoff value is 90.71%.
3. Hepatitis B virus X protein promotes B7-H6 gene activation
Yong ZOU ; Xiaoan YANG ; Changlong ZHEN ; Xingfei PAN ; Qihuan XU
Chinese Journal of Experimental and Clinical Virology 2018;32(3):255-258
Objective:
To investigate the key factor(s) of hepatitis B virus X protein (HBx) promoting B7-H6 gene activation.
Methods:
The DNA fragments of the B7-H6 promoter were amplified from the human genomic DNA using polymerase chain reaction(PCR). Products of PCR were digested by